重症胰腺炎患者应用乌司他丁联合奥曲肽治疗的效果研究  

Study on the Therapeutic Effect of Combination Therapy of Ulinastatin and Octreotide in Patients with Severe Pancreatitis

作　　者：唐艳波 韩露 王文强 TANG Yanbo;HAN Lu;WANG Wenqiang(Department of Emergency Medicine,Xinyi People’s Hospital,Xinyi Jiangsu 221400,China)

机构地区：[1]新沂市人民医院急诊内科,江苏新沂221400

出　　处：《中国医药指南》2025年第3期70-73,共4页Guide of China Medicine

摘　　要：目的探究乌司他丁联合奥曲肽治疗重症胰腺炎的应用效果。方法选择2022年7月至2023年7月新沂市人民医院就诊的56例重症胰腺炎患者,用随机数字表法分为对照组(28例)采用奥曲肽治疗,观察组(28例)采用奥曲肽联合乌司他丁治疗,以临床症状消失时间(腹胀消失时间、腹痛消失时间、肠鸣音消失时间)、炎性因子(白细胞介素-6、肿瘤坏死因子-α、超敏C反应蛋白)、肠黏膜屏障功能(D-乳糖、二胺氧化酶、内毒素水平)为本研究对比指标。结果干预前两组患者炎性因子、肠黏膜屏障功能比较无统计学意义(P>0.05),干预后观察组患者各临床指标消失时间、炎性因子水平及各肠黏膜屏障功能指标均低于对照组(P<0.05)。结论重症胰腺炎患者实施单一奥曲肽和奥曲肽联合乌司他丁两种治疗方法的比较之下,奥曲肽联合乌司他丁在改善患者临床症状,降低炎性因子水平,修复肠黏膜屏障功能方面效果更加显著,选择优越性更高。Objective To explore the application effect of combination therapy of Ulinastatin and Octreotide in the treatment of severe pancreatitis.Methods Fifty-six patients with severe pancreatitis treated in Xinyi People’s Hospital from July 2022 to July 2023 were selected and divided into control group(28 cases)with octreotide treatment and observation group(28 cases)with octreotide combined with ulinastatin treatment by random number table method.The duration of clinical symptoms(abdominal distention duration,abdominal pain duration,intestinal sound duration),inflammatory factors(interleukin-6,tumor necrosis factor-α,hypersensitive C-reactive protein),and intestinal mucosal barrier function(D-lactose,dimethylamine oxidase,endotoxin levels)were used as comparative indicators in this study.Results Before intervention,there was no statistical significance in inflammatory factors and intestinal mucosal barrier function between the two groups(P>0.05).After intervention,the disappearance time of clinical indicators,the level of inflammatory factors and the level of intestinal mucosal barrier indicators in the observation group were lower than those in the control group(P<0.05).Conclusions Compared with octreotide alone and octreotide combined with ulinastatin in the treatment of patients with severe pancreatitis,octreotide combined with ulinastatin has a more significant effect in improving clinical symptoms,reducing the level of inflammatory factors and repairing intestinal mucosal barrier function,and the selection has higher advantages.

关 键 词：重症胰腺炎 乌司他丁 奥曲肽 炎性因子 肠黏膜屏障功能 

分 类 号：R576[医药卫生—消化系统]